Marker Therapeutics Inc. [NASDAQ: MRKR] closed the trading session at $2.86 on 03/22/21. The day’s price range saw the stock hit a low of $2.75, while the highest price level was $3.30. The company report on March 17, 2021 that Marker Therapeutics, Inc. Announces Closing of Public Offering of Common Stock.
Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, announced the closing of an underwritten public offering of 32,282,857 shares of its common stock at a public offering price of $1.75 per share. The gross proceeds to Marker from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $56.5 million.
Piper Sandler & Co. acted as the sole active book-running manager for the offering. Cantor Fitzgerald & Co. also acted as a book-running manager for the offering. Oppenheimer & Co. Inc. acted as the lead manager and Roth Capital Partners acted as the co-manager for the offering.
The stocks have a year to date performance of 97.24 percent and weekly performance of 50.53 percent. The stock has been moved at 67.25 percent over the last six months. The stock has performed 0.70 percent around the most recent 30 days and changed 79.87 percent over the most recent 3-months.
If compared to the average trading volume of 2.12M shares, MRKR reached to a volume of 42785148 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Marker Therapeutics Inc. [MRKR]:
Cantor Fitzgerald have made an estimate for Marker Therapeutics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on March 19, 2021. While these analysts kept the previous recommendation, Piper Sandler dropped their target price from $5 to $2.50. The new note on the price target was released on May 12, 2020, representing the official price target for Marker Therapeutics Inc. stock.
The Average True Range (ATR) for Marker Therapeutics Inc. is set at 0.33, with the Price to Sales ratio for MRKR stock in the period of the last 12 months amounting to 353.15. The Price to Book ratio for the last quarter was 5.11, with the Price to Cash per share for the same quarter was set at 0.35.
MRKR stock trade performance evaluation
Marker Therapeutics Inc. [MRKR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 50.53. With this latest performance, MRKR shares gained by 0.70% in over the last four-week period, additionally plugging by 67.25% over the last 6 months – not to mention a rise of 74.39% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MRKR stock in for the last two-week period is set at 61.75, with the RSI for the last a single of trading hit 67.20, and the three-weeks RSI is set at 59.41 for Marker Therapeutics Inc. [MRKR]. The present Moving Average for the last 50 days of trading for this stock 2.33, while it was recorded at 2.16 for the last single week of trading, and 1.89 for the last 200 days.
Marker Therapeutics Inc. [MRKR]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Marker Therapeutics Inc. [MRKR] shares currently have an operating margin of -6188.25. Marker Therapeutics Inc.’s Net Margin is presently recorded at -6149.74.
Return on Total Capital for MRKR is now -68.63, given the latest momentum, and Return on Invested Capital for the company is -68.69. Return on Equity for this stock declined to -80.37, with Return on Assets sitting at -62.42. When it comes to the capital structure of this company, Marker Therapeutics Inc. [MRKR] has a Total Debt to Total Equity ratio set at 44.83. Additionally, MRKR Total Debt to Total Capital is recorded at 30.95, with Total Debt to Total Assets ending up at 26.87. Long-Term Debt to Equity for the company is recorded at 43.40, with the Long-Term Debt to Total Capital now at 29.97.
Reflecting on the efficiency of the workforce at the company, Marker Therapeutics Inc. [MRKR] managed to generate an average of -$652,411 per employee. Receivables Turnover for the company is 0.88 with a Total Asset Turnover recorded at a value of 0.01.Marker Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.80 and a Current Ratio set at 3.80.
Earnings per share (EPS) analysis for Marker Therapeutics Inc. [MRKR] stock
With the latest financial reports released by the company, Marker Therapeutics Inc. posted -0.14/share EPS, while the average EPS was predicted by analysts to be reported at -0.11/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -27.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MRKR.
Marker Therapeutics Inc. [MRKR]: Insider Ownership positions
There are presently around $40 million, or 17.20% of MRKR stock, in the hands of institutional investors. The top three institutional holders of MRKR stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 5,000,000, which is approximately 0% of the company’s market cap and around 29.89% of the total institutional ownership; BLACKROCK INC., holding 2,066,417 shares of the stock with an approximate value of $5.91 million in MRKR stocks shares; and AISLING CAPITAL MANAGEMENT LP, currently with $5.72 million in MRKR stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Marker Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 25 institutional holders increased their position in Marker Therapeutics Inc. [NASDAQ:MRKR] by around 578,524 shares. Additionally, 22 investors decreased positions by around 627,170 shares, while 18 investors held positions by with 12,873,075 shares. The mentioned changes placed institutional holdings at 14,078,769 shares, according to the latest SEC report filing. MRKR stock had 8 new institutional investments in for a total of 151,602 shares, while 6 institutional investors sold positions of 285,646 shares during the same period.